Alliance pharmaceutique pancanadienne (APP) – dernières mises à jour

État Nombre total Résumé
En négociation 30 Non liées à l’oncologie : 14
Liées à l’oncologie : 16
Négociations envisagées 22 Non liées à l’oncologie : 12
Liées à l’oncologie : 10
Négociations terminées 895 Avec lettre d’intention : 773
Sans entente : 122
Négociations qui n’ont pas eu lieu 114

Activités de l’APP dans les quatre dernières semaines

Voici les activités des quatre dernières semaines. Veuillez prendre note que le traitement de ces mises à jour peut prendre d’une à deux semaines.

Lettres d’engagement transmises au cours des quatre dernières semaines

Marque Fabricant Indication Date d’engagement
Carvykti Janssen Inc. For the treatment of adult patients with multiple myeloma, who have received 1 to 3 prior lines of therapy including a proteasome inhibitor and an immunomodulatory agent, and who are refractory to lenalidomide.
Carvykti Janssen Inc. (du) Multiple myeloma in adult patients who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 antibody and who are refractory to their last treatment
Venclexta AbbVie Corporation Calquence, in combination with venetoclex, for the treatment of patients with previously untreated chronic lymphocytic leukemia (CLL)
Calquence AstraZeneca Canada Inc. Indicated in combination with venetoclax for the treatment of patients with previously untreated CLL.
Verzenio Eli Lilly Canada Inc. For the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative advanced or metastatic breast cancer, in combination with an aromatase inhibitor (AI) in postmenopausal women as initial endocrine-based therapy.
Verzenio Eli Lilly Canada Inc. For the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer as follows: • in combination with an aromatase inhibitor in postmenopausal women as initial endocrine-based therapy. • in combination with fulvestrant in women with disea
Talvey Janssen Inc. For the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody, and have demonstrat
tbc (golimumab) Jamp Pharma Corporation Rheumatoid Arthritis (RA) - Psoriatic Arthritis (PsA) - Ankylosing Spondylitis (AS) - Non-radiographic Axial Spondyloarthritis (nr Ax SpA) - Ulcerative Colitis (UC)
Talzenna Pfizer Canada ULC ​In combination with enzalutamide for the treatment of adult patients with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
Movantik Knight Therapeutics Inc. Treatment of opioid-induced constipation (OIC) in adult patients with cancer and non-cancer pain who have had an inadequate response to laxative(s).

Négociations achevées dans les quatre dernières semaines avec une lettre d’intention

Marque Fabricant Indication Date d’engagement Date d’achèvement
Opdivo-Yervoy Bristol Myers Squibb Canada Inc. For the first-line treatment of adult patients with unresectable or advanced hepatocellular carcinoma (HCC).
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal-growth factor receptor (EGFR) Exon 19 deletions or Exon 21 L858R substitution mutations, who
Lazcluze and Rybrevant Janssen Inc. For the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations
Darzalex SC Janssen Inc. in combination with bortezomib, lenalidomide, and dexamethasone, followed by maintenance treatment in combination with lenalidomide, for the treatment of patients with newly diagnosed multiple myeloma who are eligible for autologous stem cell transplant.
Rybrevant Janssen Inc. In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with locally advanced (not amenable to curative therapy) or metastatic non-small cell lung cancer (NSCLC) with activating epidermal-growth factor receptor (EGFR)

Négociations achevées dans les quatre dernières semaines sans entente

Marque Fabricant Indication Date d’engagement Date d’achèvement
Ofev Boehringer Ingelheim (Canada) Ltd. Idiopathic pulmonary fibrosis and PF-ILD
Spevigo Boehringer Ingelheim (Canada) Ltd. generalized pustular psoriasis (GPP)
Tysabri Biogen Canada Inc. Multiple Sclerosis, Relapsing-Remitting
Penthrox Knight Therapeutics Inc. Adult patients undergoing minor gynecological, ambulatory, or emergency procedures
Signifor LAR Recordati Rare Diseases Canada Inc. Acromegaly in Adults

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines

Marque Fabricant Indication Aucune date de négociation

Négociations que l’APP a décidé de ne pas entreprendre dans les quatre dernières semaines